| Hans-Günter Meyer-Thompson | Buprenorphin
Second Injectable Buprenorphine Product Shows Promise
Second Injectable Buprenorphine Product Shows Promise
SAN DIEGO, California ― An injectable, subcutaneous form of buprenorphine (CAM2038, Braeburn Pharmaceuticals) demonstrated noninferiority to sublingual buprenorphine tablets for opioid use disorder (OUD) in new research findings.
Results of a randomized phase 3 efficacy and safety trial show that the drug, which can be administered weekly or monthly, may be a second injectable option for improving adherence and reducing misuse of the drug. (Medscape, 21.12.2017)